pharma

Showing 15 posts of 2905 posts found.

shutterstock_273326141

Covis Group to acquire AMAG Pharmaceuticals in $647m deal

October 5, 2020
Sales and Marketing AMAG Pharmaceuticals, Covis group, acquisition, pharma

Luxembourg-based Covis Group is set to acquire Massachusetts-based AMAG Pharmaceuticals in a new deal worth approximately $647 million on an …

covid_cell_1

Pharmafile.com’s weekly COVID-19 news round-up

September 30, 2020
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing pharma, top ten

The coronavirus news this week focuses on the development of treatments to alleviate symptoms of the virus, as Australian biotech …

european_commission_web

Jyseleca secures European approval in rheumatoid arthritis

September 28, 2020
Research and Development, Sales and Marketing Europe, Jyseleca, arthritis, pharma

The European Commission has awarded approval to Gilead and Galpagos for their oral JAK inhibitor Jyseleca (filgotinib) as a treatment …

shutterstock_2

AstraZeneca and Samsung Biologics partner up in $330m manufacturing and supply deal

September 22, 2020
Manufacturing and Production AstraZeneca, Samsung BioLogics, manufacturing, pharma

AstraZeneca has announced a new global manufacturing and supply partnership with Samsung Biologics, said to be worth a potential $330.8 …

merckincweb

Positive five-year Keytruda survival data revealed at ESMO in metastatic, PD-L1+ non-small cell lung cancer

September 22, 2020
Manufacturing and Production, Research and Development ESMO 2020, MSD, keytruda, pharma

MSD took the opportunity at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 to unveil new Phase 3 …

shutterstock_159488225

Piqray and Faslodex combo extends survival in HR+/HER2-, PIK3CA+ advanced breast cancer at ESMO 2020

September 21, 2020
Research and Development, Sales and Marketing Cancer, ESMO 2020, Novartis, pharma

New data has been unveiled for the combination of Novartis’ Piqray (alpelisib) with AstraZeneca’s Faslodex (fulvestrant) in the treatment of …

libtayo

Promising Phase 2 data for Sanofi and Regeneron’s PD-1 inhibitor Libtayo in locally advanced basal cell carcinoma

September 18, 2020
Medical Communications, Research and Development Cancer, ESMO 2020, Libtayo, Regeneron, Sanofi, pharma

Promising Phase 2 data has been released at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 for Sanofi …

lilly_building_with_american_flag_web

Lilly’s baricitinib/remdesivir combo lowers recovery time in hospitalised COVID-19 patients, according to new data

September 15, 2020
Manufacturing and Production, Research and Development COVID-19, Eli Lilly, pharma, remdesivir

Eli Lilly has unveiled promising new data from a study investigating the efficacy of baricitinib when combined with with Gilead’s …

shutter

MSD partners up with Seattle Genetics in two oncology development deals potentially worth over $4bn

September 15, 2020
Manufacturing and Production, Sales and Marketing MSD, Seattle Genetics, deal, pharma

MSD has signed two new oncology-based deals with Seattle Genetics which together could be worth up to around $4.4 billion. …

spotlighton-aprile-cw_covid-19-and-cancer-1-img

Oncology research in the age of COVID-19

September 14, 2020
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CAR T, CAR-T, Cancer, feature, pharma

Matt Fellows investigates the new challenges facing the oncology space and explores the strategies that can carry it through the disruptive …

shutterstock_273326141

Gilead scoops up Immunomedics in deal worth $21 billion

September 14, 2020
Sales and Marketing Gilead, Immunomedics, acquisition, pharma

The Board of Directors from both companies have unanimously agreed for Gilead to acquire Immunomedics for $88 per share in …

AstraZeneca slams brakes on COVID-19 vaccine trial over unexplained participant illness

September 9, 2020
Research and Development AstraZeneca, COVID-19, pharma

Global trials for AstraZeneca’s much-hyped COVID-19 vaccine, currently in development in partnership with the University of Oxford, have been halted …

shutterstock_512649

Takeda to sell another non-core portfolio for $260 million to Cheplapharm

September 8, 2020
Manufacturing and Production, Sales and Marketing Cheplapharm, Takeda, pharma

Takeda has revealed it has agreed to divest its non-core portfolio of prescription therapies to Cheplapharm in exchange for an …

sanofi_hq__boetie_hall_web

Extension study reveals Dupixent’s benefit can last up to three years in moderate-to-severe asthma

September 8, 2020
Manufacturing and Production, Research and Development Dupixent, Sanofi, asthma, pharma

New findings have been revealed from an extension study of Sanofi’s interleukin-4 (IL-4) and interleukin-13 (IL-13) inhibitor Dupixent (dupilumab) in …

Latest content